These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 12609827)

  • 41. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
    Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
    Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peripheral blood T cell subsets as prognostic indicators of chemotherapy outcome in AIDS patients with large cell lymphoma.
    Patarca R; Freidlander A; Harrington WJ; Cabral L; Byrnes JJ; Fletcher MA
    AIDS Res Hum Retroviruses; 1996 May; 12(8):645-9. PubMed ID: 8744574
    [No Abstract]   [Full Text] [Related]  

  • 43. Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.
    Djunic I; Jevtovic DL; Ranin J; Salemovic D; Tomin D; Mihaljevic B
    Biomed Pharmacother; 2008 Jan; 62(1):12-5. PubMed ID: 17629445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma.
    Xu J; Oki Y; Saksena A; Desai P; Lin P; Tang G; Yin CC; You MJ; Thakral B; Medeiros LJ; Li S
    Hum Pathol; 2017 Feb; 60():160-166. PubMed ID: 27816715
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients.
    Boulanger E; Agbalika F; Maarek O; Daniel MT; Grollet L; Molina JM; Sigaux F; Oksenhendler E
    Hematol J; 2001; 2(3):172-9. PubMed ID: 11920242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MACOP-B chemotherapy for the treatment of high-grade lymphomas in patients with HIV-1 infection.
    Taillan B; Garnier G; Ferrari E; Pesce A; Vinti H; Fuzibet JG; Dujardin P
    Acta Haematol; 1993; 89(1):10-2. PubMed ID: 7683165
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.
    Gutierrez M; Chabner BA; Pearson D; Steinberg SM; Jaffe ES; Cheson BD; Fojo A; Wilson WH
    J Clin Oncol; 2000 Nov; 18(21):3633-42. PubMed ID: 11054436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.
    Kopmar NE; Quach K; Gooley TA; Martino CH; Cherian S; Percival MM; Halpern AB; Ghiuzeli CM; Oehler VG; Abkowitz JL; Walter RB; Cassaday RD
    JAMA Oncol; 2024 Jul; 10(7):961-965. PubMed ID: 38722664
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma.
    García-Suárez J; Flores E; Callejas M; Arribas I; Gil-Fernández JJ; Olmedilla G; Curto N; Guillén H; Casco CR; Martín Y; Burgaleta C
    Br J Haematol; 2013 Feb; 160(4):510-4. PubMed ID: 23228045
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HIV-related lymphoma treated with maintenance thalidomide.
    Larson ML; Enschede SH; Gregory SA
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):231-4; discussion 234-5. PubMed ID: 16166993
    [No Abstract]   [Full Text] [Related]  

  • 52. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
    Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
    Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
    Davids MS; Rogers KA; Tyekucheva S; Wang Z; Pazienza S; Renner SK; Montegaard J; Ihuoma U; Lehmberg TZ; Parry EM; Wu CJ; Jacobson CA; Fisher DC; Thompson PA; Brown JR
    Blood; 2022 Feb; 139(5):686-689. PubMed ID: 34788401
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endoscopic appearance of AIDS-related gastrointestinal lymphoma with c-MYC rearrangements: case report and literature review.
    Tanaka S; Nagata N; Mine S; Igari T; Kobayashi T; Sugihara J; Honda H; Teruya K; Kikuchi Y; Oka S; Uemura N
    World J Gastroenterol; 2013 Aug; 19(29):4827-31. PubMed ID: 23922484
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG).
    Hentrich M; Hoffmann C; Mosthaf F; Müller M; Siehl J; Wyen C; Hensel M; ;
    Ann Hematol; 2014 Jun; 93(6):913-21. PubMed ID: 24807241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience.
    Huang H; Lin Z; Lin X; Cai Q; Xia Z; Jiang W
    Leuk Lymphoma; 2011 Jun; 52(6):1041-8. PubMed ID: 21599590
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
    O'Reilly SE; Hoskins P; Klimo P; Connors JM
    Ann Oncol; 1991 Jan; 2 Suppl 1():17-23. PubMed ID: 1710485
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
    Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma.
    Hoffmann C; Wolf E; Fätkenheuer G; Buhk T; Stoehr A; Plettenberg A; Stellbrink HJ; Jaeger H; Siebert U; Horst HA
    AIDS; 2003 Jul; 17(10):1521-9. PubMed ID: 12824790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. AIDS-related systemic non-Hodgkin's lymphoma at a large community program.
    Vilchez RA; Kozinetz CA; Jorgensen JL; Kroll MH; Butel JS
    AIDS Res Hum Retroviruses; 2002 Mar; 18(4):237-42. PubMed ID: 11860669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.